PBH
NYSE · Pharmaceuticals
Prestige Consumer Healthcare
$61.13
-0.87 (-1.40%)
Financial Highlights (FY 2026)
Revenue
1.06B
Net Income
199.68M
Gross Margin
55.8%
Profit Margin
18.9%
Rev Growth
+1.5%
D/E Ratio
0.55
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 55.8% | 55.8% | 54.1% | 54.1% |
| Operating Margin | 29.6% | 26.6% | 32.4% | 26.3% |
| Profit Margin | 18.9% | 17.9% | 30.0% | 31.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.06B | 1.04B | 462.83M | 441.46M |
| Gross Profit | 590.30M | 581.34M | 250.19M | 238.64M |
| Operating Income | 313.36M | 277.74M | 150.18M | 116.02M |
| Net Income | 199.68M | 176.98M | 138.88M | 138.12M |
| Gross Margin | 55.8% | 55.8% | 54.1% | 54.1% |
| Operating Margin | 29.6% | 26.6% | 32.4% | 26.3% |
| Profit Margin | 18.9% | 17.9% | 30.0% | 31.3% |
| Rev Growth | +1.5% | +1.5% | +15.0% | +3.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 506.23M | 506.23M | 1.29B | 1.07B |
| Total Equity | 914.76M | 914.76M | 1.56B | 1.69B |
| D/E Ratio | 0.55 | 0.55 | 0.82 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 328.55M | 307.39M | 217.92M | 202.17M |
| Free Cash Flow | — | — | 109.94M | 68.20M |